H.C. Wainwright lowered the firm’s price target on UroGen Pharma (URGN) to $40 from $50 and keeps a Buy rating on the shares. The firm revised long-term sales projections post the Q2 report.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI
- Urogen Pharma’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Tara Bancroft
- UroGen Pharma reports Q2 EPS ($1.05), consensus (83c)
- UroGen Pharma announces 24-month DOR for Phase 3 ENVISION trial
- UroGen Pharma announces publication of Phase 3b ZUSDURI study results